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The authors regret that in the production of Table 2 for this paper, information regarding data for ritonavir boosted drugs was omitted.
An amended version of Table 2 is now appearing.
Table 2
A simple scheme to rank CSF-penetrating drugs or the CNS-penetration effectiveness (CPE) ranks, proposed by Letendre et al. (2008a). Rank based on the drug physicochemical
characteristics, measured CSF concentrations and CNS efﬁcacy data extracted from publicly available information. Ritonavir boosted = r.
Low Intermediate High
NRTIs Tenofovir (PMPA) Stavudine (d4T) Zidovudine (AZT)
Didanosine (ddI) Lamivudine (3TC) Abacavir
Zalcitabine (ddC) Emtricitabine (FTC)
NNRTIs Efavirenz Delavirdine
Nevirapine






The authors would like to apologise for any inconvenience this may have caused to the authors of this article and the readers of the
journal.
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